Meeting Banner
Abstract #0901

Testing the Efficacy of GdDO3NI: A Novel Hypoxia-Targeting T1 Contrast Agent

Shubhangi Agarwal1, Carlos Renteria1, Xiangxing Kong2, Yanqing Tian2, and Vikram Kodibagkar1

1School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, United States, 2Biodesign Institute, Arizona State University, Tempe, AZ, United States

Tumor hypoxia is a severe problem in oncology, leading to enhanced metastatic potential and poor response to therapies. The advent of GdDO3NI—a hypoxia-binding contrast agent, serves to facilitate therapies by highlighting hypoxic regions on tumors. Relaxivity studies were performed and image registration were executed between modalities to validate the efficacy of this novel contrast agent to pimonidazole: the gold standard for immunohistochemical hypoxia imaging. Results showed a strong correlation in tumor boundaries and hypoxic fractions between modalities. The hypoxic regions showed lower correlation than expected however, attributed to the difference in tissue content resulting from discrepancies in slice thickness.

This abstract and the presentation materials are available to members only; a login is required.

Join Here